Scope of the Study
Doxorubicin is a type of chemotherapy drug called an anthracycline. It is used as a chemotherapy medication to treat cancer patients. The doxorubicin market has high growth prospects owing to growing prevalence of cancer and increasing use of drug in the treatment of cancer.Also, increasing clinical trail of new treatment procedures boosting the growth of the doxorubicin market. Further, increasing investment in healthcare and technological advancement expected to drive the demand for doxorubicin over the forecasted period.
The market study is being classified by Type (Lyophilized Powder and Doxorubicin Injection), by Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast Cancer, Gastric Cancer and Others) and major geographies with country level break-up.
Johnson & Johnson Services (United States), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceuticals Industries Ltd. (India), Intas Pharmaceuticals Limited (United Kingdom), Pfizer Ltd (United States), Meiji Seika Pharma Co (Japan), MicroBiopharm Japan Co (Japan), Cipla (India), Cadila Pharmaceuticals (India) and Thymoorgan Pharmazie GmbH (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Glenmark Pharmaceuticals Ltd. (India) and SRS Pharmaceuticals (India).
Research Analyst at AMA predicts that Asia Pacific Players will contribute to the maximum growth of Global Doxorubicin market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Doxorubicin market by Type, Application and Region.
On the basis of geography, the market of Doxorubicin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Prevalence of Cancer Worldwide
- Increasing Use of Drug in the Treatment of Cancer
- Increasing Awareness Programs for Cancer Treatment
- Technological Advancement and Increasing Clinical Trail of New Treatment Procedures
- Stringent Government Regulation on Doxorubicin
- High Production Cost
- Rising Demand of Doxorubicin Due to Increasing Number of Breast and Lung Cancer Patients in Various Region especially Asia Pacific
- Increasing Investment in Healthcare Industry Providing Opportunities for Various Manufacturers
- Side Effects such as Nausea ,Hair Loss, Vomiting etc.
Market Leaders and their expansionary development strategies
In 30 July, Pfizer Inc. announced the successful completion of its acquisition of Array BioPharma Inc., development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.
The U. S. Food and Drug Administration approved doxorubicin hydrochloride liposome injection, a generic version of DOXIL Injection for the treatment of ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy and for AIDS-related Kaposiís sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy.
Key Target AudienceDoxorubicin Manufacturer, Doxorubicin Suppliers/Distributors, Research and Development Firm, Government Bodies and Potential Investor
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase